Home » Agenda » Day 2

Day 2

3RD PATIENT CENTRICITY & COLLABORATION WORLD CONGRESS 2022 AMERICAS

Understanding the Patient Journey, Enabling a more Patient-Centric Approach

Washington, VA, USA | 1st - 2nd September 2022

Day 2 - Friday 2nd September 2022

  • Auditorium 1

CHALLENGES & POTENTIALS OF PATIENT ENGAGEMENT

  • Why diversity and inclusion in clinical trials are crucial?
  • Understanding critical barriers to minority and underserved patient communities participation in clinical trials
  • Actionable ways to improve diversity in clinical trials
  • What can the industry do to promote more diversity in the future?
  • Latest guidelines that make healthcare more inclusive

Tricia Mullins, Global Head, Patient Advocacy, Atara Biotherapeutics

  • What do we really know about patient safety, both as an industry and an individual and what are the challenges weface?
  • How can technology play a role in ensuring patient safety, compliance and pharmacovigilance?
  • How we can leverage individual and collective data to ensure proper care and Quality of life while reducing damage,saving time and money.

Christine Von Raesfeld, Founder & CEO, People with Empathy

Kristof Vanfraechem, Founder & CEO, Data For Patients

Carolina Consuegra, Co-Founder, Marketing & Strategy Director, Science2People

  • Incorporating robust and meaningful patient engagement for a more informed decision-making
  • Strategies and best practices in facilitating patient recruitment and retention in clinical trials
  • Enhance understanding and use appropriate methods to capture patient understanding of the benefits and riskoutcomes
  • How to best communicate patient information to support decision-making
  • Recognising key areas to ensure patients’ experiences, perspectives, needs, and priorities are captured and meaningfullyincorporated into drug development and evaluation.
  • Patient’s input to improve quality, relevance, safety and efficacy of drug development
  • Challenges and opportunities for patient-centric product design
  • The role of respective stakeholders and the way they interact, from the early steps of drug development to access inreal life?
  • The importance of data democratization
  • Common challenges in clinical data review that hinders clinical trials
  • Strategies in overcoming these challenges
  • How to seamlessly integrate data from a variety of sources?
  • How to improve safety review efficiencies and reduce the timeline to critical studies?
  • What it takes to get it right and how to avoid common pitfalls
  • Key priorities and opportunities for advocacy during COVID-19 and beyond
  • New ways of thinking to ensure the industry remains a credible and valuable partner now and in the future
  • Better collaboration between industry and patient organisations leads to improvements in patient care

14:15- 14:45, 14:50 - 15:20 - ROUND TABLE DISCUSSIONS - divided between 2 sessions of 30 mins. (5 mins. to change table)- Attendees have 2 round table options to attend

  • Learn how medical PTSD impacts patients ranging from newly diagnosed to long-term care
  • Understand the category of ways medical PTSD can develop
  • Discover opportunities for patients and providers to collaborate to alleviate symptoms of medical PTSD

Emily Parks, Founder, POP! Pissed Off Patients

  • Putting the patient first achieves the best experience and outcome for that person and their family
  • Improve communication from staff shift-changes in a hospital to getting the patient discharged faster
  • Setting expectations soon
  • Updating goals and outcomes; timely

Barby Ingle, President, International Pain Foundation

  • COVID-19 pandemic has highlighted the need for patient-centricity, understanding the drivers for innovation in pharma
  • Partnering with patients and placing patient well-being at the core of all initiatives
  • Shifting towards disease-oriented to patient-centric
  • Innovative approaches for direct-to-patient assume significant importance for driving patient-centricity
  • Technologies that enhance the patient-centricity in pharma
Scroll to Top